Lupus

In Systemic Lupus Erythematosus, Glucocorticoid Dose Linked to Adverse Events and Overall Costs

By Wayne Kuznar

San Diego, CA—High doses patients with of glucocorticoids in the treatment of patients with systemic lupus erythematosus (SLE) are associated with a greater incidence of adverse events (AEs) and greater healthcare resource utilization compared with low doses or no use of glucocorticoids, found Wei-Shi Yeh, PhD, Associate Director, Global Market Access, Biogen Idec, Weston, MA, and colleagues.

Consideration of Pathogenesis Leads to Appropriate Therapy in Patients with Severe Thrombocytopenia and Lupus

By Wayne Kuznar

San Diego, CA—The selection of treatment for patients with systemic lupus erythematosus and thrombocytopenia should hinge on the differential diagnosis and the pathogenic mechanisms involved. Three possible options include splenectomy, B-cell depletion, and platelet augmentation, said Brady L. Stein, MD, MHS, Assistant Professor of Medicine, Northwestern University, Chicago, IL, at the 2013 American College of Rheumatology meeting.

Challenges in Lupus Management

Easy on the prednisone, maximize immunomodulators, look for noncalcified plaque

By Wayne Kuznar

San Diego, CA—Expanded use of hydroxychloroquine and limited use of prednisone are 2 strategies in the management of patients with systemic lupus erythematosus (SLE), said Michelle A. Petri, MD, MPH, Professor of Medicine, Johns Hopkins University, Baltimore, MD, at the 2013 American College of Rheumatology meeting.

The Lupus Initiative Helps Eliminate Disparities in Patient Care

By Wayne Kuznar

San Diego, CA—Inadequate lupus-specific education and a lack of autoimmune centers are leading to a delay in the diagnosis of lupus, especially among ethnic minorities, who are disproportionately affected by lupus.

BTK Inhibitors Show Promise in Lupus

By Neil Canavan

The new class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors may hold the key to more effective treatment for systemic lupus erythematosus (SLE), according to the results of a study just published in the peer-reviewed journal Arthritis & Rheumatism (Mina-Osorio P, et al. 2013;65:2380-2391).

New Diagnostic Algorithm for SLE Can Facilitate Early Treatment, Improve Outcomes

By Rosemary Frei, MSc

The diagnosis of systemic lupus erythematosus (SLE) is challenging, because of the heterogeneous nature of this disease. Early disease is especially challenging because patients often present with severe but uncharacteristic features. A team of rheumatologists has created a diagnostic algorithm based on the differential diagnosis of SLE (Bertsias GK, et al. Nat Rev Rheumatol. 2013 July 9 [Epub ahead of print]).

Survey Shows Significant Disease Burden on Patients with Lupus and Limitations of Current Treatment Regimens

Corticosteroids associated with most side effects, patient dissatisfaction

By Rosemary Frei, MSc

An independent survey conducted in 2012 and recently published of patients with systemic lupus erythematosus (SLE) and their physicians confirms the significant burden SLE confers on patients in quality of life and work productivity and the limitations of currently available drug regimens in relieving the considerable impairment (Strand V, et al. Lupus. 2013;22:819-826). Despite the limitations of the treatment regimens in controlling disease activity, patients and physicians reported overall satisfaction with current treatment regimens.

Biomarker Discovery in Lupus Has Much Room for Growth

By Wayne Kuznar

Although biomarker progress is easily discernible in cardiology and oncology, researchers are only at the beginning of the long, winding road of biomarker discovery in lupus, said Mary K. Crow, MD, Physician-in-Chief, and Chair, Division of Rheumatology, and Director of the Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York City, at the 2012 meeting of the American College of Rheumatology.

Latest Treatment Options for Lupus

By Phoebe Starr

The goal of treating lupus is to induce improvement and maintain it, said Bevra Hahn, MD, Chief, Department of Rheumatology and Arthritis, University of California at Los Angeles.

Cancer Drug Shows Promise in Treating Lupus

By David Hawk

Berlin, Germany—A small study presented during a press conference at the 2012 European League Against Rheu­ma­­tism Congress sparked a great deal of interest among rheumatology re­searchers when it was reported that use of the cancer drug bor­tezomib showed a dramatic reduction in symptom scores in patients with systemic lupus erythematosus (SLE) who are refractory to the current standard of care.